Gossamer Bio Announces Data Presentations at the American Heart Association Scientific Sessions 2019

Gossamer Bio, Inc. GOSS, a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that two abstracts supporting GB002, the Company's inhaled PDGFR inhibitor for the treatment of pulmonary arterial hypertension (PAH), have been accepted for presentation at the American Heart Association (AHA) Scientific Sessions 2019 being held November 16- 18 in Philadelphia, Pennsylvania.

Details for the AHA presentations are as follows:

Session Type: Abstract Rapid Fire Oral
Session Title: Novel Experimental Therapies for Pulmonary Arterial Hypertension
Session Date and Time: Sunday, November 17, 2019; 10:30- 11:20 a.m. ET
Abstract Control Number: 12947
Abstract Title: In Vivo Efficacy of a Novel, Inhaled PDGFRa/b Inhibitor, GB002, In The Rat Monocrotaline and Pneumonectomy Model of Pulmonary Arterial Hypertension
Presenter Name: Larry Zisman, MD, FACC
Presentation Date/Time: Sunday, November 17, 2019; 10:50- 10:55 a.m. ET
Presentation Number: RF272
Location: Zone 4, Science and Technology Hall, Level 2, Halls A-D

Session Type: Moderated Digital Poster Session
Session Title: Pathophysiology of RV Failure, HFpEF and PAH
Session Date and Time: Monday, November 18, 2019; 2:05- 2:55 p.m. ET
Abstract Control Number: 11102
Abstract Title: GB002, A Novel Inhaled PDGFR Kinase Inhibitor, Demonstrates Efficacy in The Su5416 Hypoxia Rat Model Of Pulmonary Arterial Hypertension (PAH)
Presenter Name: Anna Galkin, PhD
Presentation Date/Time: Monday, November 18, 2019; 2:35- 2:40 p.m. ET
Presentation Number: MDP428
Location: Moderated Posters 2, Science and Technology Hall, Level 2, Halls A-D

About Gossamer Bio

Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Its goal is to be an industry leader in each of these therapeutic areas and to enhance and extend the lives of patients suffering from such diseases.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191111005056/en/